Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13217212 | 0.87 | NQO2 (0.47) | KDM4ANPSR1CTSSCTSKBCHE | |
| SCHEMBL31721189 | 0.87 | KDM4A (0.44) | KDM4ANPSR1BCHEDYRK1ACA12 | |
| SCHEMBL31721309 | 0.85 | KDM4A (0.43) | KDM4ANPSR1BCHEDYRK1ACA12 | |
| SCHEMBL112919 | 0.81 | NPSR1 (0.49) | KDM4ANPSR1BCHECA12CA1 | |
| SCHEMBL26616825 | 0.81 | NPSR1 (0.49) | KDM4ANPSR1BCHECA12CA1 | |
| SCHEMBL9296950 | 0.80 | NPSR1 (0.70) | NPSR1CA12CA9ADORA2A | |
| SCHEMBL2962806 | 0.80 | ALDH1A1 (0.38) | NPSR1CTSSCTSK | |
| SCHEMBL1629274 | 0.80 | NPSR1 (0.47) | KDM4ANPSR1BCHECA12CA1 | |
| SCHEMBL29510880 | 0.80 | NPSR1 (0.47) | KDM4ANPSR1BCHECA12CA1 | |
| SCHEMBL13940974 | 0.80 | NPSR1 (0.51) | KDM4ANPSR1BCHECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180044376-A1 | Method for Preparing Largazole Analogs and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20180044376-A1 | Method for Preparing Largazole Analogs and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| WO-2016144665-A1 | METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144665-A1 | METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2016-09-15 | — | — | WO | disclosed |
| US-9186402-B2 | Method for preparing largazole analogs and uses thereof | Colorado State University Research University (US) | 2015-11-17 | — | — | US | disclosed |
| US-8513290-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-08-20 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| WO-2010009334-A1 | METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | KDM4A 3144/4885NPSR1 1631/4885CTSS 3122/4885 |
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | CYP51A1, ADPRS, LPXN | KDM4A 1717/4885NPSR1 3135/4885CTSS 2063/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | KDM4A 2746/4885NPSR1 4629/4885CTSS 3291/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | KDM4A 3144/4885NPSR1 1631/4885CTSS 3122/4885 |
| US-20180044376-A1 | Method for Preparing Largazole Analogs and Uses Thereof | CYP51A1, ADPRS, LPXN | KDM4A 1717/4885NPSR1 3135/4885CTSS 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.